320 related articles for article (PubMed ID: 33216696)
1. Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role?
Stonier T; Tin AL; Sjoberg DD; Jibara G; Vickers AJ; Fine S; Eastham J
J Urol; 2021 Apr; 205(4):1063-1068. PubMed ID: 33216696
[TBL] [Abstract][Full Text] [Related]
2. Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.
Falagario UG; Beksac AT; Martini A; Cumarasamy S; Gupta A; Prasad S; Thulasidass H; Shah QN; Jayaratna I; Lewis S; Rastinehad AR; Taouli B; Cormio L; Carrieri G; Tewari AK
J Urol; 2019 Jul; 202(1):102-107. PubMed ID: 30730408
[TBL] [Abstract][Full Text] [Related]
3. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy.
Gandaglia G; Ploussard G; Valerio M; Mattei A; Fiori C; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Moschini M; Zamboni S; Rakauskas A; Tian Z; Karakiewicz PI; De Cobelli F; Porpiglia F; Montorsi F; Briganti A
Eur Urol; 2020 Jun; 77(6):733-741. PubMed ID: 31547938
[TBL] [Abstract][Full Text] [Related]
4. Staging Accuracy of Multiparametric Magnetic Resonance Imaging in Caucasian and African American Men Undergoing Radical Prostatectomy.
Falagario UG; Ratnani P; Lantz A; Jambor I; Dovey Z; Verma A; Treacy PJ; Sobotka S; Martini A; Bashorun H; Ashan M; Wagaskar VG; Lewis S; Cormio L; Carrieri G; Kyprianou N; Mohamed N; Tewari A
J Urol; 2020 Jul; 204(1):82-90. PubMed ID: 31977261
[TBL] [Abstract][Full Text] [Related]
5. Development and External Validation of a Multiparametric Magnetic Resonance Imaging and International Society of Urological Pathology Based Add-On Prediction Tool to Identify Prostate Cancer Candidates for Pelvic Lymph Node Dissection.
Draulans C; Everaerts W; Isebaert S; Van Bruwaene S; Gevaert T; Oyen R; Joniau S; Lerut E; De Wever L; Laenen A; Weynand B; Defraene G; Vanhoutte E; De Meerleer G; Haustermans K
J Urol; 2020 Apr; 203(4):713-718. PubMed ID: 31718396
[TBL] [Abstract][Full Text] [Related]
6. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
Deniffel D; Salinas E; Ientilucci M; Evans AJ; Fleshner N; Ghai S; Hamilton R; Roberts A; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA; Perlis N
J Urol; 2020 Dec; 204(6):1187-1194. PubMed ID: 32496160
[TBL] [Abstract][Full Text] [Related]
7. Targeted Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy for Quantitative Gleason 4 Grading Prediction in Radical Prostatectomy Specimens: Implications for Active Surveillance Candidate Selection.
Kachanov M; Budäus L; Beyersdorff D; Karakiewicz PI; Tian Z; Falkenbach F; Tilki D; Maurer T; Sauter G; Graefen M; Leyh-Bannurah SR
Eur Urol Focus; 2023 Mar; 9(2):303-308. PubMed ID: 36184537
[TBL] [Abstract][Full Text] [Related]
8. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
[TBL] [Abstract][Full Text] [Related]
9. MRI lesion size is more important than the number of positive biopsy cores in predicting adverse features and recurrence after radical prostatectomy: implications for active surveillance criteria in intermediate-risk patients.
Baboudjian M; Uleri A; Beauval JB; Touzani A; Diamand R; Roche JB; Lacetera V; Lechevallier E; Roumeguère T; Simone G; Benamran D; Fourcade A; Fiard G; Peltier A; Ploussard G
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):318-322. PubMed ID: 37452146
[TBL] [Abstract][Full Text] [Related]
10. Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms for Predicting Adverse Pathology in Prostate Cancer.
Rayn KN; Bloom JB; Gold SA; Hale GR; Baiocco JA; Mehralivand S; Czarniecki M; Sabarwal VK; Valera V; Wood BJ; Merino MJ; Choyke P; Turkbey B; Pinto PA
J Urol; 2018 Nov; 200(5):1041-1047. PubMed ID: 29852182
[TBL] [Abstract][Full Text] [Related]
11. Novel nomogram for the prediction of seminal vesicle invasion including multiparametric magnetic resonance imaging.
Martini A; Gupta A; Cumarasamy S; Lewis SC; Haines KG; Briganti A; Montorsi F; Tewari AK
Int J Urol; 2019 Apr; 26(4):458-464. PubMed ID: 30659663
[TBL] [Abstract][Full Text] [Related]
12. Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer.
Hegde JV; Chen MH; Mulkern RV; Fennessy FM; D'Amico AV; Tempany CM
Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):e101-7. PubMed ID: 23040223
[TBL] [Abstract][Full Text] [Related]
13. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
[TBL] [Abstract][Full Text] [Related]
14. Identifying Men Who Can Remain on Active Surveillance Despite Biopsy Reclassification to Grade Group 2 Prostate Cancer.
Baraban E; Erak E; Fatima A; Akbari A; Zhao J; Fletcher SA; Bhanji Y; de la Calle CM; Mamawala M; Landis P; Macura KJ; Pavlovich CP; Epstein JI
J Urol; 2023 Jul; 210(1):99-107. PubMed ID: 37042826
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
16. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
[TBL] [Abstract][Full Text] [Related]
17. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
18. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
Tan N; Shen L; Khoshnoodi P; Alcalá HE; Yu W; Hsu W; Reiter RE; Lu DY; Raman SS
J Urol; 2018 May; 199(5):1218-1223. PubMed ID: 29128577
[TBL] [Abstract][Full Text] [Related]
19. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
[TBL] [Abstract][Full Text] [Related]
20. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
